Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1/2 1

Status

Active not recruiting 3Completed 2Recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Colorectal Neoplasms 39Stomach Neoplasms 30Rectal Neoplasms 21Pancreatic Neoplasms 16Colonic Neoplasms 16Lymphoma, Large B-Cell, Diffuse 14Esophageal Neoplasms 13Adenocarcinoma Of Esophagus 12Carcinoma, Non-Small-Cell Lung 11Neoplasms 9Neoplasm Metastasis 9Adenocarcinoma 9Cholangiocarcinoma 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Ovarian Neoplasms 6Biliary Tract Neoplasms 6Esophageal Squamous Cell Carcinoma 4Endometrial Neoplasms 4Carcinoma, Hepatocellular 4Lymphoma, Non-Hodgkin 3Lymphoma 3Lung Neoplasms 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Carcinoma 3Bile Duct Neoplasms 3Advanced Solid Tumors 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Spinocerebellar Degenerations 2

Interventions

pembrolizumab 52Paclitaxel 19Carboplatin 15Cisplatin 13lenvatinib 10Docetaxel 8Saline Solution 7Capecitabine 7Pemetrexed 6Oxaliplatin 6Gemcitabine 6Fluorouracil 6olaparib 5Leucovorin 5Albumin-Bound Paclitaxel 5belzutifan 4Bevacizumab 4130-nm albumin-bound paclitaxel 4patritumab deruxtecan 3Glucose 3Acetaminophen 3liposomal doxorubicin 2Levoleucovorin 2Irinotecan 2Histamine H2 Antagonists 2Histamine Antagonists 2Etoposide 2Doxorubicin 2Dexamethasone 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Oxaliplatin × 90 days × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05239741 2026-05-22

MK-3475-C66

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
100 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03221426 2026-03-09

KEYNOTE-585

Merck Sharp & Dohme LLC

Phase 3 Completed
1,007 enrolled 25 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

Merck Sharp & Dohme LLC

Phase 3 Completed
120 enrolled 17 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡